Obstructive sleep disordered breathing in children: beyond adenotonsillectomy.
Traditionally, adenotonsillectomy (AT) has long been the treatment of choice for obstructive sleep disordered breathing (SDB) in children. AT is usually considered a safe procedure, which cures 80% of children with SDB. Accumulated data have however challenged this overly simplistic view. Indeed, AT is invariably associated with significant morbidity, post-operative pain, and a mortality rate which, though low, cannot be ignored. In addition, aside from a recurrence of SDB at adolescence in an unknown percentage of cases, some recent results suggest that complete SDB cure is not achieved in as much as 75% of cases after AT. Interestingly, several treatment options have been recently proposed for replacing or complementing AT. Continuous positive airway pressure (CPAP) is now suggested in children with remaining SDB after AT; however, compliance and suitability of equipment remain important hurdles, especially in small children and infants. Anti-inflammatory treatments, including nasal glucocorticoids and/or the anti-leukotriene montelukast, appear to hold great promise. Finally, orthodontic treatments are an appealing option, with recent results in children suggesting that it is possible to improve or perhaps even cure SDB in a durable manner by enlarging the nasal passages and/or the oropharyngeal airspace. In conclusion, while we are currently in the midst of an exciting time with several new treatments being developed for childhood SDB, randomized controlled trials are urgently needed to delineate their indications. In the meantime, it appears that systematic detection of orthodontic anomalies and better collaboration with maxillofacial specialists, including orthodontists and/or dentists, is needed for deciding the best treatment options for childhood SDB.
Praud
Jean-Paul
JP
Respiratory Medicine Division, Department of Pediatrics, Université de Sherbrooke, Québec, Canada. jean-paul.praud@usherbrooke.ca
Dorion
Dominique
D
D000085:Acetates / Q000627:therapeutic use; D000233:Adenoidectomy / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003521:Cyclopropanes; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D009971:Orthodontics, Corrective; D011804:Quinolines / Q000627:therapeutic use; D012891:Sleep Apnea Syndromes / Q000601:surgery* / Q000628:therapy; D013440:Sulfides; D014068:Tonsillectomy / Q000009:adverse effects
D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast